BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25:2328-2338. [PMID: 24769639 DOI: 10.1093/annonc/mdu162] [Cited by in Crossref: 211] [Cited by in F6Publishing: 275] [Article Influence: 26.4] [Reference Citation Analysis]
Number Citing Articles
1 Ho J, Fiocco C, Spencer K. Treating Biliary Tract Cancers: New Targets and Therapies. Drugs 2022. [DOI: 10.1007/s40265-022-01808-x] [Reference Citation Analysis]
2 Ohaegbulam KC, Koethe Y, Fung A, Mayo SC, Grossberg AJ, Chen EY, Sharzehi K, Kardosh A, Farsad K, Rocha FG, Thomas CR, Nabavizadeh N. The multidisciplinary management of cholangiocarcinoma. Cancer 2022. [DOI: 10.1002/cncr.34541] [Reference Citation Analysis]
3 Maßmann M, Treckmann J, Markus P, Schumacher B, Albers D, Ting S, Mende B, Roehrle J, Virchow I, Rosery V, Laue K, Zaun G, Kostbade K, Pogorzelski M, Schmid KW, Baba H, Siveke JT, Paul A, Schildhaus HU, Schuler M, Wiesweg M, Kasper S. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04424-0] [Reference Citation Analysis]
4 Roth GS, Neuzillet C, Sarabi M, Edeline J, Malka D, Lièvre A. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalized medicine ? European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.11.006] [Reference Citation Analysis]
5 Tam VC, Ramjeesingh R, Burkes R, Yoshida EM, Doucette S, Lim HJ. Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective. Current Oncology 2022;29:7072-7085. [DOI: 10.3390/curroncol29100555] [Reference Citation Analysis]
6 Andersen LB, Mahler MSK, Andersen RF, Jensen LH, Raunkilde L. The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. Cancers 2022;14:4598. [DOI: 10.3390/cancers14194598] [Reference Citation Analysis]
7 Shi GM, Huang XY, Wen TF, Song TQ, Kuang M, Mou HB, Bao LQ, Zhao HT, Zhao H, Feng XL, Zhang BX, Peng T, Zhang YB, Li XC, Yu HS, Cao Y, Liu LX, Zhang T, Wang WL, Ran JH, Liu YB, Gong W, Chen MX, Cao L, Luo Y, Wang Y, Zhou H, Yang GH, Fan J, Zhou J. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study. Cancer Med 2022. [PMID: 36127767 DOI: 10.1002/cam4.5273] [Reference Citation Analysis]
8 Abou-alfa GK, Bibeau K, Schultz N, Yaqubie A, Millang B, Ren H, Féliz L. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Targ Oncol. [DOI: 10.1007/s11523-022-00906-w] [Reference Citation Analysis]
9 Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2022. [PMID: 36083140 DOI: 10.1002/hep.32771] [Reference Citation Analysis]
10 Park CS, Sung MJ, Kim SJ, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer. Cancers (Basel) 2022;14:4323. [PMID: 36077857 DOI: 10.3390/cancers14174323] [Reference Citation Analysis]
11 Leem G, Jang S, Cho J, Jo JH, Lee HS, Chung MJ, Park JY, Bang S, Yoo D, Cheon H, Kim J, Lim K, Jung I, Im J, Chung Y, Park SW. Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial. Cancers 2022;14:4229. [DOI: 10.3390/cancers14174229] [Reference Citation Analysis]
12 Yu H, Xu Y, Gao W, Li M, He J, Deng X, Xing W. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. Front Oncol 2022;12:930611. [DOI: 10.3389/fonc.2022.930611] [Reference Citation Analysis]
13 Neuzillet C, Malka D, Lièvre A, Khurana IS, Vernerey D. Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: analysis of aggregated data from a systematic literature review. Clin Res Hepatol Gastroenterol 2022;:102010. [PMID: 35988887 DOI: 10.1016/j.clinre.2022.102010] [Reference Citation Analysis]
14 Walden D, Eslinger C, Bekaii-Saab T. Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements. Therap Adv Gastroenterol 2022;15:17562848221115317. [PMID: 35967919 DOI: 10.1177/17562848221115317] [Reference Citation Analysis]
15 Hu S, Molina L, Tao J, Liu S, Hassan M, Singh S, Poddar M, Bell A, Sia D, Oertel M, Raeman R, Nejak-Bowen K, Singhi A, Luo J, Monga SP, Ko S. NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma. Gastroenterology 2022;163:449-65. [PMID: 35550144 DOI: 10.1053/j.gastro.2022.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Haag F, Manikkam A, Kraft D, Bär C, Wilke V, Nowak AJ, Bertrand J, Omari J, Pech M, Gylstorff S, Relja B. Selective Internal Radiotherapy Changes the Immune Profiles of Extracellular Vesicles and Their Immune Origin in Patients with Inoperable Cholangiocarcinoma. Cells 2022;11:2309. [DOI: 10.3390/cells11152309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sun W, Wan W, Gao Z, Suo T, Shen S, Liu H. Publication Trends of Research on Gallbladder Cancer During 2001–2021: A 20-Year Bibliometric Analysis. Front Oncol 2022;12:932797. [DOI: 10.3389/fonc.2022.932797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, Cristoferi L, Ciaccio A, Cortinovis DL, Invernizzi P, Massironi S. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol 2022;27:100737. [PMID: 35809836 DOI: 10.1016/j.aohep.2022.100737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Martin RCG, Simo KA, Hansen P, Rocha F, Philips P, Mcmasters KM, Tatum CM, Kelly LR, Driscoll M, Sharma VR, Crocenzi TS, Scoggins CR. Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11932-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liddell SS, Chakrabarti S, Wintheiser GA, Zemla TJ, Shi Q, Tella SH, Jin Z, Wookey VB, Hassan H, Tran NH, Borad MJ, Mahipal A. Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precis Oncol 2022;6:e2200003. [PMID: 35772047 DOI: 10.1200/PO.22.00003] [Reference Citation Analysis]
21 Cho SM, Esmail A, Raza A, Dacha S, Abdelrahim M. Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma. Cancers (Basel) 2022;14:2641. [PMID: 35681621 DOI: 10.3390/cancers14112641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Bibeau K, Féliz L, Lihou CF, Ren H, Abou-Alfa GK. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. JCO Precis Oncol 2022;6:e2100414. [PMID: 35544727 DOI: 10.1200/PO.21.00414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zhou J, Sun Y, Zhang W, Yuan J, Peng Z, Wang W, Gong J, Yang L, Cao Y, Zhao H, Chen C, Wang W, Shen L, Zhou A. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology 2022. [PMID: 35491432 DOI: 10.1002/hep.32548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li J, Cen W, Tong C, Wang L, Zhang W, Deng S, Yu J, Lu B. Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis. PLoS ONE 2022;17:e0266738. [DOI: 10.1371/journal.pone.0266738] [Reference Citation Analysis]
25 Lee Y, Oh SY, Kim KM, Go S, Kim JH, Huh SJ, Kang JH, Ji JH. Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study. Cancers 2022;14:1950. [DOI: 10.3390/cancers14081950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Khankhel ZS, Goring S, Bobiak S, Lamy FX, Nayak D, Garside J, Reese ES, Schoenherr N. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety. Future Oncol 2022. [PMID: 35387496 DOI: 10.2217/fon-2021-1302] [Reference Citation Analysis]
27 Vogel A, Saborowski A. Aktuelle Systemtherapie für fortgeschrittene biliäre Tumoren. Onkologe 2022;28:287-298. [DOI: 10.1007/s00761-022-01115-w] [Reference Citation Analysis]
28 Zhao Y, Cao Y, Wang X, Qian T. Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review. OTT 2022;Volume 15:345-51. [DOI: 10.2147/ott.s353743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kang S, El-Rayes BF, Akce M. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2022;14:1748. [PMID: 35406520 DOI: 10.3390/cancers14071748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Kim H, Kim R, Kim HR, Jo H, Kim H, Ha SY, Park JO, Park YS, Kim ST. HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Front Oncol 2022;12:834104. [PMID: 35252005 DOI: 10.3389/fonc.2022.834104] [Reference Citation Analysis]
31 Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns M, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 2022;4:100417. [DOI: 10.1016/j.jhepr.2021.100417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hack J, Crabb S. Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Salati M, Marcheselli L, Messina C, Merz V, Messina M, Carotenuto P, Caputo F, Gelsomino F, Spallanzani A, Reggiani Bonetti L, Caramaschi S, Luppi G, Dominici M, Ghidini M. Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy. CMAR 2022;Volume 14:983-93. [DOI: 10.2147/cmar.s346235] [Reference Citation Analysis]
34 Massa A, Peraldo-neia C, Vita F, Varamo C, Basiricò M, Raggi C, Bernabei P, Erriquez J, Sarotto I, Leone F, Marchiò S, Cavalloni G, Aglietta M. Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. Front Oncol 2022;12:771418. [DOI: 10.3389/fonc.2022.771418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Götz M, Hammes E, Helmberger T, Hoffmann RT, Hofmann WP, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen HP, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, Schirmacher P, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns MA, Galle P, Malek N. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome. Z Gastroenterol 2022;60:e186-227. [PMID: 35148560 DOI: 10.1055/a-1589-7854] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Voesch S, Bitzer M, Malek N. [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners]. Radiologe 2022. [PMID: 35147708 DOI: 10.1007/s00117-022-00970-3] [Reference Citation Analysis]
37 Wege H, Sinn M, Stein A. Differenzialtherapie bei fortgeschrittenen Gallengangskarzinomen. Gastro-News 2022;9:45-49. [DOI: 10.1007/s15036-021-2445-3] [Reference Citation Analysis]
38 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Cho MT, Gholami S, Gui D, Tejaswi SL, Fananapazir G, Abi-jaoudeh N, Jutric Z, Samarasena JB, Li X, Valerin JB, Mercer J, Dayyani F. Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach. Cancers 2022;14:392. [DOI: 10.3390/cancers14020392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Csoma SL, Bedekovics J, Veres G, Árokszállási A, András C, Méhes G, Mokánszki A. Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing. Cancers (Basel) 2022;14:233. [PMID: 35008396 DOI: 10.3390/cancers14010233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Jo JH, Bang S, Song SY. Recent Update in Chemotherapy of Cholangiocarcinoma. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_19] [Reference Citation Analysis]
42 Spolverato G, Glavas D, Hewitt DB, Brown ZJ, Capelli G, Bergamo F, Rizzato MD, Pawlik TM. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Expert Opin Pharmacother 2021;:1-9. [PMID: 34964678 DOI: 10.1080/14656566.2021.2020250] [Reference Citation Analysis]
43 Salati M, Rizzo A, Merz V, Messina C, Francesco C, Gelsomino F, Spallanzani A, Ricci AD, Palloni A, Frega G, De Lorenzo S, Carotenuto P, Pettorelli E, Benatti S, Luppi G, Melisi D, Brandi G, Dominici M. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. Expert Rev Gastroenterol Hepatol 2021;:1-7. [PMID: 34890512 DOI: 10.1080/17474124.2022.2017772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, Goyal L, Lacy J, Li D, Patel AK, He AR, Abou-Alfa GK, Spencer K, Kim EJ, Davis SL, McRee AJ, Kunk PR, Goyal S, Liu Y, Dennison L, Xavier S, Mohan AA, Zhu Q, Wang-Gillam A, Poklepovic A, Chen HX, Sharon E, Lesinski GB, Azad NS. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest 2021;131:e152670. [PMID: 34907910 DOI: 10.1172/JCI152670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
45 Manne A, Woods E, Tsung A, Mittra A. Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology. Front Oncol 2021;11:768009. [PMID: 34868996 DOI: 10.3389/fonc.2021.768009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
46 Möhring C, Feder J, Mohr RU, Sadeghlar F, Bartels A, Mahn R, Zhou T, Marinova M, Feldmann G, Brossart P, von Websky M, Matthaei H, Manekeller S, Glowka T, Kalff JC, Weismüller TJ, Strassburg CP, Gonzalez-Carmona MA. First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis. Front Oncol 2021;11:717397. [PMID: 34858809 DOI: 10.3389/fonc.2021.717397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Voesch S, Bitzer M, Malek NP. Biliäre Karzinome: Zielstrukturen für eine molekulare Systemtherapie. Deutsches Ärzteblatt Online 2021. [DOI: 10.3238/personko.2021.11.26.01] [Reference Citation Analysis]
48 Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021;7:1669-77. [PMID: 34554208 DOI: 10.1001/jamaoncol.2021.3836] [Cited by in Crossref: 51] [Cited by in F6Publishing: 63] [Article Influence: 51.0] [Reference Citation Analysis]
49 Braun S, McSheehy P, Litherland K, McKernan P, Forster-Gross N, Bachmann F, El-Shemerly M, Dimova-Dobreva M, Polyakova I, Häckl M, Zhou P, Lane H, Kellenberger L, Engelhardt M. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma. Expert Opin Investig Drugs 2021;30:1071-80. [PMID: 34698609 DOI: 10.1080/13543784.2021.1995355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
50 Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, Kang BW, Ryu H, Lee JS, Kim KW, Abou-Alfa GK, Ryoo BY. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021;22:1560-72. [PMID: 34656226 DOI: 10.1016/S1470-2045(21)00486-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 30.0] [Reference Citation Analysis]
51 Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, Perrier H, Dahan L, Bourgeois V, Akouz FK, Soularue E, Ly VL, Molin Y, Lecomte T, Ghiringhelli F, Coriat R, Louafi S, Neuzillet C, Manfredi S, Malka D; PRODIGE 38 AMEBICA Investigators/Collaborators. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. J Clin Oncol 2021;:JCO2100679. [PMID: 34662180 DOI: 10.1200/JCO.21.00679] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 17.0] [Reference Citation Analysis]
52 Wang C, Huang M, Geng Q, Li W, Chang J, Tang W, Guo W. Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study. Ther Adv Med Oncol 2021;13:17588359211039047. [PMID: 34484431 DOI: 10.1177/17588359211039047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Wege H, Sinn M, Stein A. Differenzialtherapie bei fortgeschrittenen Gallengangskarzinomen. InFo Hämatol Onkol 2021;24:21-26. [DOI: 10.1007/s15004-021-8791-7] [Reference Citation Analysis]
54 Neuzillet C. Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00220-X. [PMID: 34358483 DOI: 10.1016/S2468-1253(21)00220-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
55 Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22:1290-300. [PMID: 34339623 DOI: 10.1016/S1470-2045(21)00336-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 73] [Article Influence: 57.0] [Reference Citation Analysis]
56 Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer.Lancet. 2021;397:428-444. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 140] [Cited by in F6Publishing: 163] [Article Influence: 140.0] [Reference Citation Analysis]
57 Filippi R, Leone F, Fornaro L, Aprile G, Casadei-Gardini A, Silvestris N, Palloni A, Satolli MA, Scartozzi M, Russano M, Lutrino SE, Lombardi P, Frega G, Garattini SK, Vivaldi C, Spadi R, Giulia O, Fenocchio E, Brunetti O, Aglietta M, Brandi G. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. J Chemother 2021;:1-10. [PMID: 34313188 DOI: 10.1080/1120009X.2021.1953887] [Reference Citation Analysis]
58 Huang P, Zhou Y, Chen Y. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. J Gastrointest Cancer 2021. [PMID: 34312770 DOI: 10.1007/s12029-021-00637-7] [Reference Citation Analysis]
59 Choi IS, Kim KH, Lee JH, Suh KJ, Kim JW, Park JH, Kim YJ, Kim JS, Kim JH, Kim JW. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer 2021;154:288-95. [PMID: 34303267 DOI: 10.1016/j.ejca.2021.06.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Loilome W, Dokduang H, Suksawat M, Padthaisong S. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. Expert Opin Investig Drugs 2021;:1-22. [PMID: 34292795 DOI: 10.1080/13543784.2021.1955102] [Reference Citation Analysis]
61 Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N. Chemotherapy for Biliary Tract Cancer in 2021. J Clin Med 2021;10:3108. [PMID: 34300274 DOI: 10.3390/jcm10143108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
62 Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply. Lancet Oncol 2021;22:e288-9. [PMID: 34197751 DOI: 10.1016/S1470-2045(21)00341-7] [Reference Citation Analysis]
63 Woodford R, Brungs D, Leighton C, Grimison P, Sjoquist KM, Becker T, Robinson S, Gebski V, Wilson K, Chantrill L, Aghmesheh M. Combination chemotherapy with NAB® -paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study). Asia Pac J Clin Oncol 2021. [PMID: 34180586 DOI: 10.1111/ajco.13599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Bhargava PG, Kumar A, Simha V, Shah M, Patkar S, Goel M, Ostwal V, Ramaswamy A. Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas-A Relatively Rare Component of Biliary Tract Cancers in India. South Asian J Cancer 2020;9:209-12. [PMID: 34268260 DOI: 10.1055/s-0041-1726140] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer 2020;8:e000564. [PMID: 32461347 DOI: 10.1136/jitc-2020-000564] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 54.0] [Reference Citation Analysis]
66 Tsujie M, Iwai T, Kubo S, Ura T, Hatano E, Sakai D, Takeda Y, Kaibori M, Kobayashi T, Katanuma A, Katayose Y, Fukase K. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. Jpn J Clin Oncol 2021;51:911-7. [PMID: 33822966 DOI: 10.1093/jjco/hyab029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Lee KJ, Park BK. The Effect of Second Line FOLFOX Chemotherapy for Advanced Biliary Tract Cancer. JDCR 2021;9:37-39. [DOI: 10.52927/jdcr.2021.9.1.37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Corrigan L, Lowery M. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:475-81. [PMID: 33836133 DOI: 10.1080/17474124.2021.1915765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
70 Zhang G, Gong S, Pang L, Hou L, He W. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study. Front Oncol 2021;11:659217. [PMID: 34012920 DOI: 10.3389/fonc.2021.659217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
71 Vogel A, Timrott K, Voigtländer T, Saborowski A. Aktuelle lokale und systemische Therapie biliärer Tumoren. Gastroenterologe 2021;16:199-207. [DOI: 10.1007/s11377-021-00514-6] [Reference Citation Analysis]
72 Wu T, Lei MS, Gao XZ, Xiong TG, Yang K, Gong Q, Tang R, Tian YP, Fu XH. lncRNA SNHG16 Mediates Cell Proliferation and Apoptosis in Cholangiocarcinoma by Directly Targeting miR-146a-5p/GATA6 Axis. Biochem Genet 2021. [PMID: 33797690 DOI: 10.1007/s10528-021-10059-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
73 Moazzami B, Majidzadeh-A K, Dooghaie-Moghadam A, Eslami P, Razavi-Khorasani N, Iravani S, Khoshdel A, Shahi F, Dashti H, Mehrvar A, Nassiri Toosi M. Cholangiocarcinoma: State of the Art. J Gastrointest Cancer 2020;51:774-81. [PMID: 32157571 DOI: 10.1007/s12029-020-00390-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
74 Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy vs active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.Lancet Oncol. 2021;22:690-701. [PMID: 33798493 DOI: 10.1016/S1470-2045(21)00027-9] [Cited by in Crossref: 160] [Cited by in F6Publishing: 127] [Article Influence: 160.0] [Reference Citation Analysis]
75 Sutherland M, Ahmed O, Zaidi A, Ahmed S. Current progress in systemic therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci 2021. [PMID: 33735541 DOI: 10.1002/jhbp.939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Talwar V, Raina S, Goel V, Dash P, Doval DC. Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer. Indian J Med Res 2020;152:475-81. [PMID: 33707389 DOI: 10.4103/ijmr.IJMR_930_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Ramaswamy A, Ostwal V, Sharma A, Bhargava P, Srinivas S, Goel M, Patkar S, Mandavkar S, Jadhav P, Parulekar M, Choudhari A, Gupta S. Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT). JAMA Oncol 2021;7:436-9. [PMID: 33270098 DOI: 10.1001/jamaoncol.2020.6166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
78 Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, Goff LW, Alberts S, Bui LA, Sanghal A, Kothekar M, Khopade A, Chimote G, Faulkner R, Eckhardt SG, Adjei AA, Jimeno A. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. Cancer Chemother Pharmacol 2021;87:779-88. [PMID: 33634324 DOI: 10.1007/s00280-021-04235-z] [Reference Citation Analysis]
79 Ueno M, Morizane C, Furukawa M, Sakai D, Komatsu Y, Nakai Y, Tsuda M, Ozaka M, Mizuno N, Muto M, Fukutomi A, Ikeda M, Tsuji A, Katanuma A, Moriwaki T, Kajiwara T, Ishii H, Negoro Y, Shimizu S, Nemoto N, Kobayashi S, Makino K, Furuse J. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. Cancer Med 2021;10:2088-99. [PMID: 33635605 DOI: 10.1002/cam4.3813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Hong Y, Li X, Cao D. Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification. Front Oncol 2021;11:538328. [PMID: 33763343 DOI: 10.3389/fonc.2021.538328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
82 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
83 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
84 Vogel A, Saborowski A. Current and Future Systemic Therapies in Biliary Tract Cancer. Visc Med 2021;37:32-8. [PMID: 33708816 DOI: 10.1159/000513969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
85 Munugala NV, Singh A, Shroff RT. Novel Targeted Therapies in Clinical Use and on the Horizon for Cholangiocarcinoma. Diagnosis and Management of Cholangiocarcinoma 2021. [DOI: 10.1007/978-3-030-70936-5_21] [Reference Citation Analysis]
86 Hessey S, Bridgewater J. Palliative Chemotherapy and Radiotherapy for Cholangiocarcinoma. Diagnosis and Management of Cholangiocarcinoma 2021. [DOI: 10.1007/978-3-030-70936-5_17] [Reference Citation Analysis]
87 Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Cancer Control 2020;27:1073274820983013. [PMID: 33356500 DOI: 10.1177/1073274820983013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
88 Maeda O, Ebata T, Shimokata T, Matsuoka A, Inada-Inoue M, Morita S, Takano Y, Urakawa H, Miyai Y, Sugishita M, Mitsuma A, Ando M, Mizuno T, Nagino M, Ando Y. Chemotherapy for biliary tract cancer: real-world experience in a single institute. Nagoya J Med Sci 2020;82:725-33. [PMID: 33311803 DOI: 10.18999/nagjms.82.4.725] [Reference Citation Analysis]
89 Shen T, Zheng S, Geng L, Liu Z, Xu J, Lin B, Qian J, Zheng S. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review. Technol Cancer Res Treat 2020;19:1533033820979703. [PMID: 33308041 DOI: 10.1177/1533033820979703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
90 Hu S, Molina L, Tao J, Liu S, Hassan M, Singh S, Poddar M, Bell A, Sia D, Oertel M, Raeman R, Nejak-bowen K, Singhi A, Luo J, Monga SP, Ko S. NOTCH-YAP1/TEAD-DNMT1 axis regulates hepatocyte reprogramming into intrahepatic cholangiocarcinoma.. [DOI: 10.1101/2020.12.03.410993] [Reference Citation Analysis]
91 Wang M, Chen Z, Guo P, Wang Y, Chen G. Therapy for advanced cholangiocarcinoma: Current knowledge and future potential. J Cell Mol Med 2021;25:618-28. [PMID: 33277810 DOI: 10.1111/jcmm.16151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
92 Cholangiocarcinoma Working Group. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment. Dig Liver Dis 2020;52:1430-42. [PMID: 32952071 DOI: 10.1016/j.dld.2020.08.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
93 Sipra QUAR, Shroff R. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. Expert Opinion on Investigational Drugs 2021;30:281-4. [DOI: 10.1080/13543784.2021.1849139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
94 Vienot A, Neuzillet C. Continuum of care for advanced biliary tract cancers. Clinics and Research in Hepatology and Gastroenterology 2020;44:810-24. [DOI: 10.1016/j.clinre.2020.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Pape UF, Kasper S, Meiler J, Sinn M, Vogel A, Müller L, Burkhard O, Caca K, Heeg S, Büchner-Steudel P, Rodriguez-Laval V, Kühl AA, Arsenic R, Jansen H, Treasure P, Utku N. Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study. Cancers (Basel) 2020;12:E3149. [PMID: 33121007 DOI: 10.3390/cancers12113149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Yoon J, Kang SY, Lee KH, Cheon GJ, Oh DY. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer. Cancer Res Treat 2021;53:471-9. [PMID: 33091966 DOI: 10.4143/crt.2020.577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Okano N, Furuse J, Ueno M, Morizane C, Yamanaka T, Ojima H, Ozaka M, Sasaki M, Takahara N, Nakai Y, Kobayashi S, Morimoto M, Hosoi H, Maeno S, Nagashima F, Ikeda M, Okusaka T. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). Oncologist 2021;26:97-e201. [PMID: 33010112 DOI: 10.1002/onco.13547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Lamarca A, Frizziero M, McNamara MG, Valle JW. Clinical and Translational Research Challenges in Biliary Tract Cancers. Curr Med Chem 2020;27:4756-77. [PMID: 31971102 DOI: 10.2174/0929867327666200123090153] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
99 Lozano E, Asensio M, Perez-Silva L, Banales JM, Briz O, Marin JJG. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. Hepatology 2020;72:949-64. [PMID: 31863486 DOI: 10.1002/hep.31088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
100 Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules 2020;25:E3754. [PMID: 32824685 DOI: 10.3390/molecules25163754] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
101 Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, Manoharan P, Palmer D, Bridgewater J, Valle JW. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. J Natl Cancer Inst. 2020;112:200-210. [PMID: 31077311 DOI: 10.1093/jnci/djz071] [Cited by in Crossref: 37] [Cited by in F6Publishing: 51] [Article Influence: 18.5] [Reference Citation Analysis]
102 Xie C, McGrath NA, Monge Bonilla C, Fu J. Systemic treatment options for advanced biliary tract carcinoma. J Gastroenterol 2020;55:944-57. [PMID: 32748173 DOI: 10.1007/s00535-020-01712-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
103 Jansen H, Pape UF, Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol 2020;11:770-89. [PMID: 32953160 DOI: 10.21037/jgo-20-203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
104 Bartolini I, Risaliti M, Fortuna L, Agostini C, Ringressi MN, Taddei A, Muiesan P. Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments. Radiol Oncol 2020;54:263-71. [PMID: 32726292 DOI: 10.2478/raon-2020-0045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
105 Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.Cancers (Basel). 2020;12. [PMID: 32722188 DOI: 10.3390/cancers12082039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
106 Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, Segatto O, Vogel A, Macias RIR, Rodrigues PM, Casta A, Mertens J, Rodrigues CMP, Fernandez-Barrena MG, Da Silva Ruivo A, Marzioni M, Mentrasti G, Acedo P, Munoz-Garrido P, Cardinale V, Banales JM, Valle JW, Bridgewater J, Braconi C; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer 2020;123:1047-59. [PMID: 32694694 DOI: 10.1038/s41416-020-0987-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
107 Neuzillet C, Casadei-Gardini A, Brieau B, Vivaldi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Le Sourd S, Evesque L, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues) Investigators., GICO (Italian Group of Cholangiocarcinoma) Investigators. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. Int J Cancer 2020;147:3177-88. [PMID: 32525595 DOI: 10.1002/ijc.33146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
108 Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol 2020; 26(25): 3542-3561 [PMID: 32742125 DOI: 10.3748/wjg.v26.i25.3542] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
109 Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J Hepatol 2020;73:170-85. [PMID: 32171892 DOI: 10.1016/j.jhep.2020.03.007] [Cited by in Crossref: 156] [Cited by in F6Publishing: 156] [Article Influence: 78.0] [Reference Citation Analysis]
110 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
111 Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol 2020;16:2375-84. [PMID: 32580579 DOI: 10.2217/fon-2020-0299] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 17.0] [Reference Citation Analysis]
112 Lamarca A, Valle JW. Reaching out beyond first-line treatments in advanced biliary tract cancers. Ann Oncol 2020;31:1099-102. [PMID: 32569724 DOI: 10.1016/j.annonc.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Schönfeld L, Hinrichs JB, Marquardt S, Voigtländer T, Dewald C, Koppert W, Manns MP, Wacker F, Vogel A, Kirstein MM. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. J Cancer Res Clin Oncol 2020;146:3003-12. [PMID: 32564137 DOI: 10.1007/s00432-020-03289-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
114 Taghizadeh H, Unseld M, Schmiderer A, Djanani A, Wilthoner K, Buchinger D, Prager GW. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. Cancer Chemother Pharmacol 2020;86:109-15. [PMID: 32556829 DOI: 10.1007/s00280-020-04094-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
115 Chen L, Ma WL, Cheng WC, Yang JC, Wang HC, Su YT, Ahmad A, Hung YC, Chang WC. Targeting lipid droplet lysophosphatidylcholine for cisplatin chemotherapy. J Cell Mol Med 2020;24:7187-200. [PMID: 32543783 DOI: 10.1111/jcmm.15218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
116 Lee SH, Lee HS, Lee SH, Woo SM, Kim DU, Bang S. Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study. J Clin Med 2020;9:E1769. [PMID: 32517311 DOI: 10.3390/jcm9061769] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
117 Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clin Colorectal Cancer 2020;19:156-64. [PMID: 32513593 DOI: 10.1016/j.clcc.2020.05.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
118 Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796-807. [PMID: 32416072 DOI: 10.1016/s1470-2045(20)30157-1] [Cited by in Crossref: 347] [Cited by in F6Publishing: 376] [Article Influence: 173.5] [Reference Citation Analysis]
119 Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Zhang J, Wu L, Liu J, Lin M. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review. Immunotherapy 2020;12:555-61. [PMID: 32372672 DOI: 10.2217/imt-2019-0100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
121 Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J Clin Med 2020;9:E1353. [PMID: 32380750 DOI: 10.3390/jcm9051353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
122 Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev 2020;86:101998. [PMID: 32203843 DOI: 10.1016/j.ctrv.2020.101998] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
123 Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, Bidoli P, Invernizzi P. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Cells 2020;9:E688. [PMID: 32168869 DOI: 10.3390/cells9030688] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 16.5] [Reference Citation Analysis]
124 Saborowski A, Bathon M, Vogel A. Molekulares Tumorboard: Cholangiokarzinom. Forum 2020;35:13-16. [DOI: 10.1007/s12312-019-00728-4] [Reference Citation Analysis]
125 Javle M, Zhao H, Abou-Alfa GK. Systemic therapy for gallbladder cancer. Chin Clin Oncol 2019;8:44. [PMID: 31484490 DOI: 10.21037/cco.2019.08.14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
126 Belkouz A, de Vos-Geelen J, Mathôt RAA, Eskens FALM, van Gulik TM, van Oijen MGH, Punt CJA, Wilmink JW, Klümpen HJ. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. Br J Cancer 2020;122:634-9. [PMID: 31919404 DOI: 10.1038/s41416-019-0698-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
127 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 617] [Cited by in F6Publishing: 560] [Article Influence: 308.5] [Reference Citation Analysis]
128 Tella SH, Kommalapati A, Borad MJ, Mahipal A. Second-line therapies in advanced biliary tract cancers. The Lancet Oncology 2020;21:e29-41. [DOI: 10.1016/s1470-2045(19)30733-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 24.5] [Reference Citation Analysis]
129 Reduzzi C, Vismara M, Silvestri M, Celio L, Niger M, Peverelli G, De Braud F, Daidone MG, Cappelletti V. A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer.Int J Cancer. 2020;146:3495-3503. [PMID: 31814120 DOI: 10.1002/ijc.32822] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
130 Breder VV, Kruteleva SY, Kazantseva MA, Laktionov KK. Practical aspects of modern antineoplastic therapy in locally advanced and metastatic biliary tract cancer. Malignant Tumours 2019;9:71-81. [DOI: 10.18027/2224-5057-2019-9-3-71-81] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist 2020;25:380-e763. [PMID: 31826977 DOI: 10.1634/theoncologist.2019-0874] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
132 Kim ST, Oh SY, Lee J, Kang JH, Lee HW, Lee MA, Sohn BS, Hong JH, Park YS, Park JO, Lim HY. Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. J Cancer 2019;10:6185-90. [PMID: 31772650 DOI: 10.7150/jca.37610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
133 Filippi R, Lombardi P, Quarà V, Fenocchio E, Aimar G, Milanesio M, Leone F, Aglietta M. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opin Pharmacother 2019;20:2121-37. [PMID: 31550186 DOI: 10.1080/14656566.2019.1667335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
134 Caparica R, Lengelé A, Bekolo W, Hendlisz A. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients. Autops Case Rep 2019;9:e2019087. [PMID: 31528622 DOI: 10.4322/acr.2019.087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
135 Maltseva AP, Syutkin VE, Kolyshev IY, Rudakov VS, Svetlakova DS, Sadykhov ZA, Udalov YD, Voskanyan SE. Transplantation in oncology: the future of a multidisciplinary approach. Transplantologiâ (Mosk ) 2019;11:218-233. [DOI: 10.23873/2074-0506-2019-11-3-218-233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
136 Wensheng L, Bo Z, Qiangsheng H, Wenyan X, Shunrong J, Jin X, Quanxing N, Xianjun Y, Xiaowu X. MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine. Cancer Cell Int 2019;19:232. [PMID: 31516389 DOI: 10.1186/s12935-019-0948-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
137 Belkouz A, Labeur TA, Dierks J, Dijk F, van Oijen MG, Verheij J, van Gulik TM, van de Vijver MJ, Wilmink H, Punt CJ, Klümpen H. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 2019;141:82-94. [DOI: 10.1016/j.critrevonc.2019.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
138 Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ, Holcombe RF, Marshall JL, Morse MA. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol 2019;10:652-62. [PMID: 31392046 DOI: 10.21037/jgo.2018.08.18] [Cited by in Crossref: 52] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
139 Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol 2019;4:711-20. [PMID: 31300360 DOI: 10.1016/S2468-1253(19)30189-X] [Cited by in Crossref: 113] [Cited by in F6Publishing: 123] [Article Influence: 37.7] [Reference Citation Analysis]
140 Lamarca A, Barriuso J, Chander A, McNamara MG, Hubner RA, ÓReilly D, Manoharan P, Valle JW. (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol 2019;71:115-29. [PMID: 30797051 DOI: 10.1016/j.jhep.2019.01.038] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
141 Ying J, Chen J. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data. Critical Reviews in Oncology/Hematology 2019;139:134-42. [DOI: 10.1016/j.critrevonc.2019.01.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
142 White J, Carolan-Rees G, Dale M, Patrick HE, See TC, Bell JK, Manas DM, Crellin A, Slevin NJ, Sharma RA. Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study. J Vasc Interv Radiol 2019;30:1185-92. [PMID: 31255499 DOI: 10.1016/j.jvir.2019.03.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
143 Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4:611-621. [PMID: 31109808 DOI: 10.1016/s2468-1253(19)30086-x] [Cited by in Crossref: 142] [Cited by in F6Publishing: 116] [Article Influence: 47.3] [Reference Citation Analysis]
144 Qin BD, Jiao XD, Liu K, Wu Y, He X, Liu J, Qin WX, Wang Z, Zang YS. Basket Trials for Intractable Cancer. Front Oncol 2019;9:229. [PMID: 31032221 DOI: 10.3389/fonc.2019.00229] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
145 Moik F, Riedl JM, Winder T, Terbuch A, Rossmann CH, Szkandera J, Bauernhofer T, Kasparek AK, Schaberl-Moser R, Reicher A, Prinz F, Pichler M, Stöger H, Stotz M, Gerger A, Posch F. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis. Sci Rep 2019;9:5548. [PMID: 30944390 DOI: 10.1038/s41598-019-42069-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
146 He L, Deng H, Lei J, Yi F, Li J, Fan X, Wei Y, Xu J, Zhang W. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies. BMC Cancer 2019;19:276. [PMID: 30922256 DOI: 10.1186/s12885-019-5487-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
147 Tamma R, Annese T, Ruggieri S, Brunetti O, Longo V, Cascardi E, Mastropasqua MG, Maiorano E, Silvestris N, Ribatti D. Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. Eur J Clin Invest 2019;49:e13087. [PMID: 30767196 DOI: 10.1111/eci.13087] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
148 Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues)., GICO (Italian Group of Cholangiocarcinoma) Investigators., Gustave Roussy Institute Cohort., Barts Cancer Institute Cohort. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer 2019;111:94-106. [PMID: 30826661 DOI: 10.1016/j.ejca.2019.01.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
149 Labib PL, Fusai GK, Pereira SP. Cholangiocarcinoma. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch29] [Reference Citation Analysis]
150 Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P. GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma. Invest New Drugs 2019;37:1135-45. [DOI: 10.1007/s10637-019-00741-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
151 Jin N, Abushahin L. Systemic Therapy. Intrahepatic Cholangiocarcinoma 2019. [DOI: 10.1007/978-3-030-22258-1_8] [Reference Citation Analysis]
152 Pickles O, Ma YT. Oncotherapies for Cholangiocarcinoma. Liver Cancers 2019. [DOI: 10.1007/978-3-319-92216-4_17] [Reference Citation Analysis]
153 Mizrahi JD, Abdel-wahab R, Javle M. Clinical Trials and Novel/Emerging Treatment. Intrahepatic Cholangiocarcinoma 2019. [DOI: 10.1007/978-3-030-22258-1_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Cotton J, Lamarca A, Mcnamara MG, Valle JW. Novel Treatments for Advanced Cholangiocarcinoma. Liver Cancers 2019. [DOI: 10.1007/978-3-319-92216-4_18] [Reference Citation Analysis]
155 Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F. Biliary tract cancer: current challenges and future prospects. Cancer Manag Res. 2019;11:379-388. [PMID: 30643463 DOI: 10.2147/cmar.s157156] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
156 Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165-171. [PMID: 30420614 DOI: 10.1038/s41416-018-0334-0] [Cited by in Crossref: 189] [Cited by in F6Publishing: 198] [Article Influence: 47.3] [Reference Citation Analysis]
157 Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, Pusceddu S. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treat Rev 2019;72:45-55. [PMID: 30476750 DOI: 10.1016/j.ctrv.2018.11.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 56] [Article Influence: 11.5] [Reference Citation Analysis]
158 Lamarca A, Barriuso J, Mcnamara MG, Valle JW. Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treatment Reviews 2018;70:168-77. [DOI: 10.1016/j.ctrv.2018.09.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
159 Lamarca A, Galdy S, Barriuso J, Moghadam S, Beckett E, Rogan J, Backen A, Billington C, McNamara MG, Hubner RA, Cramer A, Valle JW. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS One 2018;13:e0206007. [PMID: 30335866 DOI: 10.1371/journal.pone.0206007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
160 Takahara N, Nakai Y, Isayama H, Sasaki T, Saito K, Oyama H, Kanai S, Suzuki T, Sato T, Hakuta R, Ishigaki K, Takeda T, Saito T, Mizuno S, Kogure H, Tada M, Koike K. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases. Invest New Drugs 2018;36:1093-102. [PMID: 30324343 DOI: 10.1007/s10637-018-0670-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
161 Saborowski A, Vogel A. Das intrahepatische Gallengangskarzinom – Diagnostik und Therapie. Wien klin Mag 2018;21:220-225. [DOI: 10.1007/s00740-018-0251-0] [Reference Citation Analysis]
162 Jo JH, Song SY. Chemotherapy of Cholangiocarcinoma: Current Management and Future Directions. Topics in the Surgery of the Biliary Tree 2018. [DOI: 10.5772/intechopen.76134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Saborowski A, Vogel A. Das intrahepatische Gallengangskarzinom – Diagnostik und Therapie. Gastroenterologe 2018;13:366-371. [DOI: 10.1007/s11377-018-0280-7] [Reference Citation Analysis]
164 Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol 2018;3:40. [PMID: 30148225 DOI: 10.21037/tgh.2018.07.02] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 10.3] [Reference Citation Analysis]
165 Ikeda M, Ohno I, Ueno H, Mitsunaga S, Hashimoto Y, Okusaka T, Kondo S, Sasaki M, Sakamoto Y, Takahashi H, Hara R, Kobayashi S, Nakamura O, Morizane C. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Invest New Drugs 2019;37:109-17. [PMID: 29995287 DOI: 10.1007/s10637-018-0634-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
166 Zheng Y, Tu X, Zhao P, Jiang W, Liu L, Tong Z, Zhang H, Yan C, Fang W, Wang W. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer 2018;119:291-5. [PMID: 29955136 DOI: 10.1038/s41416-018-0138-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
167 Sachs TE, Akintorin O, Tseng J. How Should Gallbladder Cancer Be Managed? Adv Surg 2018;52:89-100. [PMID: 30098623 DOI: 10.1016/j.yasu.2018.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
168 Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist 2018;23:1407-e136. [PMID: 29853658 DOI: 10.1634/theoncologist.2018-0044] [Cited by in Crossref: 92] [Cited by in F6Publishing: 99] [Article Influence: 23.0] [Reference Citation Analysis]
169 Squires MH, Woelfel I, Cloyd JM, Pawlik TM. Emerging treatment options for cholangiocarcinoma. Expert Opinion on Orphan Drugs 2018;6:527-36. [DOI: 10.1080/21678707.2018.1476235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Saletti P, Zaniboni A. Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. J Gastrointest Oncol 2018;9:377-89. [PMID: 29755778 DOI: 10.21037/jgo.2018.01.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
171 Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4:CD011746. [PMID: 29624208 DOI: 10.1002/14651858.cd011746.pub2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
172 Chong DQ, Zhu AX. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget. 2016;7:46750-46767. [PMID: 27102149 DOI: 10.18632/oncotarget.8775] [Cited by in Crossref: 63] [Cited by in F6Publishing: 79] [Article Influence: 15.8] [Reference Citation Analysis]
173 Harrington J, Carter L, Basu B, Cook N. Drug development and clinical trial design in pancreatico-biliary malignancies. Curr Probl Cancer 2018;42:73-94. [PMID: 29402439 DOI: 10.1016/j.currproblcancer.2018.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
174 Deng A, Cohen S. Current and Emerging Medical Therapies for Advanced Disease in Intrahepatic Cholangiocarcinoma. Primary and Metastatic Liver Tumors 2018. [DOI: 10.1007/978-3-319-91977-5_11] [Reference Citation Analysis]
175 Ikeda M, Ioka T, Fukutomi A, Morizane C, Kasuga A, Takahashi H, Todaka A, Okusaka T, Creasy CL, Gorman S, Felitsky DJ, Kobayashi M, Zhang F, Furuse J. Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Cancer Sci 2018;109:215-24. [PMID: 29121415 DOI: 10.1111/cas.13438] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
176 Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A. Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer 2017;87:122-30. [PMID: 29145038 DOI: 10.1016/j.ejca.2017.10.013] [Cited by in Crossref: 84] [Cited by in F6Publishing: 91] [Article Influence: 16.8] [Reference Citation Analysis]
177 Kobayashi S, Ueno M, Sugimori K, Morizane C, Kojima Y, Irie K, Goda Y, Morimoto M, Ohkawa S. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer. Cancer Chemother Pharmacol 2017;80:1189-96. [PMID: 29071413 DOI: 10.1007/s00280-017-3461-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
178 Vogel A, Schirmer P, Kirstein MM. Aktuelle Therapieoptionen beim Cholangiokarzinom. Gastroenterologe 2017;12:423-433. [DOI: 10.1007/s11377-017-0191-z] [Reference Citation Analysis]
179 Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017;7:943-962. [PMID: 28818953 DOI: 10.1158/2159-8290] [Cited by in F6Publishing: 115] [Reference Citation Analysis]
180 Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov 2017;7:943-62. [PMID: 28818953 DOI: 10.1158/2159-8290.CD-17-0245] [Cited by in Crossref: 272] [Cited by in F6Publishing: 300] [Article Influence: 54.4] [Reference Citation Analysis]
181 Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2017; 9(7): 268-280 [PMID: 28808500 DOI: 10.4251/wjgo.v9.i7.268] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
182 Pounds R, Leonard S, Dawson C, Kehoe S. Repurposing itraconazole for the treatment of cancer. Oncol Lett 2017;14:2587-97. [PMID: 28927025 DOI: 10.3892/ol.2017.6569] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
183 Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP, Wacker F, Vogel A. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol 2017;143:2113-21. [DOI: 10.1007/s00432-017-2461-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
184 Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Cho H, Ryoo BY, Chang HM. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol 2017;80:209-15. [PMID: 28597043 DOI: 10.1007/s00280-017-3353-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
185 Shirahama T, Muroya D, Matsueda S, Yamada A, Shichijo S, Naito M, Yamashita T, Sakamoto S, Okuda K, Itoh K, Sasada T, Yutani S. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. Cancer Sci 2017;108:838-45. [PMID: 28188670 DOI: 10.1111/cas.13193] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
186 Gordo AJ, Gómez ML, Casado E, Molina R. Actualización en cáncer de páncreas y de vías biliares. Medicine - Programa de Formación Médica Continuada Acreditado 2017;12:1919-1928. [DOI: 10.1016/j.med.2017.04.013] [Reference Citation Analysis]
187 Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer 2017;116:1402-7. [PMID: 28441383 DOI: 10.1038/bjc.2017.119] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
188 Ramaswamy A, Ostwal V, Pande N, Sahu A, Jandyal S, Ramadwar M, Shetty N, Patkar S, Goel M, Gupta S. Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option. J Gastrointest Cancer 2016;47:305-12. [PMID: 27211249 DOI: 10.1007/s12029-016-9828-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
189 Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol 2017;8:314-23. [PMID: 28480070 DOI: 10.21037/jgo.2016.09.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
190 Ostwal V, Pinninti R, Ramaswamy A, Shetty N, Goel M, Patkar S, Mirani J, Nashikkar C, Banavali S. Treatment of advanced Gall bladder cancer in the real world-can continuation chemotherapy improve outcomes? J Gastrointest Oncol 2017;8:368-76. [PMID: 28480076 DOI: 10.21037/jgo.2017.03.08] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
191 Doherty MK, McNamara MG, Aneja P, McInerney E, Moignard S, Horgan AM, Jiang H, Panzarella T, Jang R, Dhani N, Hedley D, Knox JJ. Long term responders to palliative chemotherapy for advanced biliary tract cancer. J Gastrointest Oncol 2017;8:352-60. [PMID: 28480074 DOI: 10.21037/jgo.2017.03.06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
192 Guro H, Kim JW, Choi Y, Cho JY, Yoon YS, Han HS. Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. Surg Oncol 2017;26:146-52. [PMID: 28577720 DOI: 10.1016/j.suronc.2017.03.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
193 Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigaki K, Saito K, Akiyama D, Uchino R, Mizuno S, Yagioka H, Kogure H, Togawa O, Matsubara S, Ito Y, Toda N, Tada M, Koike K. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study. Invest New Drugs 2017;35:269-76. [PMID: 28124197 DOI: 10.1007/s10637-017-0430-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
194 Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, Chang HM. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017;116:561-567. [PMID: 28081540 DOI: 10.1038/bjc.2016.446] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
195 Plentz RR, Malek NP. Systemic Therapy of Cholangiocarcinoma. Visc Med 2016;32:427-30. [PMID: 28229078 DOI: 10.1159/000453084] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
196 Ebata T, Ercolani G, Alvaro D, Ribero D, Di Tommaso L, Valle JW. Current Status on Cholangiocarcinoma and Gallbladder Cancer. Liver Cancer. 2016;6:59-65. [PMID: 27995089 DOI: 10.1159/000449493] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 9.2] [Reference Citation Analysis]
197 Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11-31. [PMID: 28693792 DOI: 10.1016/j.critrevonc.2016.11.012] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 11.3] [Reference Citation Analysis]
198 Brungs D, Aghmesheh M, Sjoquist K, Goldstein D. Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review. Asia-Pac J Clin Oncol 2017;13:e291-7. [DOI: 10.1111/ajco.12638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
199 Dechêne A, Kasper S. Cholangiozelluläres Karzinom. Gastroenterologe 2016;11:400-409. [DOI: 10.1007/s11377-016-0096-2] [Reference Citation Analysis]
200 Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D;  ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v28-v37. [PMID: 27664259 DOI: 10.1093/annonc/mdw324] [Cited by in Crossref: 350] [Cited by in F6Publishing: 377] [Article Influence: 58.3] [Reference Citation Analysis]
201 Unseld M, Scheithauer W, Weigl R, Kornek G, Stranzl N, Bianconi D, Brunauer G, Steger G, Zielinski CC, Prager GW. Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma. J Gastrointest Oncol. 2016;7:588-594. [PMID: 27563449 DOI: 10.21037/jgo.2016.05.01] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
202 Moriwaki T, Yamamoto Y, Gosho M, Kobayashi M, Sugaya A, Yamada T, Endo S, Hyodo I. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy. Br J Cancer 2016;114:881-8. [PMID: 27031848 DOI: 10.1038/bjc.2016.83] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
203 Marret G, Neuzillet C, Rousseau B, Tournigand C. [Medical management of cholangiocarcinomas in 2015]. Bull Cancer 2016;103:389-99. [PMID: 26922666 DOI: 10.1016/j.bulcan.2016.01.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
204 Sirohi B, Rastogi S, Singh A, Sheth V, Dawood S, Talole S, Ramadwar M, Kulkarni S, Shrikhande SV. Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer. Future Oncol 2015;11:1191-200. [PMID: 25832876 DOI: 10.2217/fon.14.295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
205 Jensen LH. Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. Expert Opin Investig Drugs 2016;25:359-65. [PMID: 26781267 DOI: 10.1517/13543784.2016.1142973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
206 Ho J, Curley SA. Diagnosis and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. Cancer Treat Res 2016;168:121-63. [PMID: 29206368 DOI: 10.1007/978-3-319-34244-3_7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
207 Kim HJ, Yun J, Kim HJ, Kim KH, Kim SH, Lee S, Bae SB, Kim CK, Lee NS, Lee KT, Park SK, Won J, Choi HJ, Moon JH, Hong DS. Second-Line Chemotherapy in Advanced Biliary Tract Cancer: A Retrospective Analysis. Soonchunhyang Med Sci 2015;21:75-81. [DOI: 10.15746/sms.15.017] [Reference Citation Analysis]
208 Fornaro L, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Caparello C, Musettini G, Pasquini G, Falcone A, Brandi G, Sperduti I, Vasile E; GICO group (Gruppo Italiano COlangiocarcinoma). Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. J Exp Clin Cancer Res. 2015;34:156. [PMID: 26693938 DOI: 10.1186/s13046-015-0267-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
209 Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, Belli C, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. Cancer Chemother Pharmacol 2016;77:109-14. [PMID: 26659366 DOI: 10.1007/s00280-015-2919-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
210 Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A, Laquente B, Macarulla T, Rodríguez-Mowbray JR, Maurel J. Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol 2015;17:982-7. [PMID: 26607930 DOI: 10.1007/s12094-015-1436-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
211 Plentz R, Vogel A. Therapie des metastasierten Cholangiokarzinoms. Onkologe 2015;21:1064-1068. [DOI: 10.1007/s00761-015-2932-2] [Reference Citation Analysis]
212 Harrett E, Arif SS, Mukherjee S. Management of cancer of the liver, gallbladder and biliary tract. Practical Clinical Oncology 2015. [DOI: 10.1017/cbo9781107280250.016] [Reference Citation Analysis]
213 Abdel-rahman OM, Elsayed Z. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database of Systematic Reviews 2015. [DOI: 10.1002/14651858.cd011746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
214 Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, Lecomte T, Coriat R, Bachet JB, Claudez P, Zaanan A, Soibinet P, Desrame J, Thirot-Bidault A, Trouilloud I, Mary F, Marthey L, Taieb J, Cacheux W, Lièvre A. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer 2015;121:3290-7. [PMID: 26052689 DOI: 10.1002/cncr.29471] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 11.1] [Reference Citation Analysis]
215 Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101 [PMID: 25717243 DOI: 10.3748/wjg.v21.i7.2096] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
216 Hwang IG, Jang J, Oh SY, Rho MH, Lee S, Park YS, Park JO, Nam EM, Lee HR, Jun HJ, Chi K. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. Cancer Chemother Pharmacol 2015;75:757-62. [DOI: 10.1007/s00280-015-2691-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
217 Lamarca A, Hubner R, Ryder W, Valle J. Reply to the letter to the editor ‘Second-line chemotherapy in advanced biliary cancer: the present now will later be past’ by Vivaldi et al. Annals of Oncology 2014;25:2444-5. [DOI: 10.1093/annonc/mdu382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
218 Vivaldi C, Fornaro L, Cereda S, Aprile G, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Brandi G, Vasile E. Second-line chemotherapy in advanced biliary cancer: the present now will later be past. Ann Oncol 2014;25:2443-4. [PMID: 25122694 DOI: 10.1093/annonc/mdu379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
219 Valle JW. BINGO: targeted therapy for advanced biliary-tract cancer. Lancet Oncol. 2014;15:778-780. [PMID: 24852117 DOI: 10.1016/s1470-2045(14)70238-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]